Please read our Privacy Statement and updated Terms of Use. As described further therein, we use third-party cookies to improve the operation of our site. If you require further information and/or wish to disable cookies, please visit allaboutcookies.org. X CONTACT US Investors & Media Publications Collaborators News Contact Merus Technology Pipeline Careers The new face of fighting cancer The battle against cancer has raged for decades and the end game is nearing. Merus’ innovative bispecific antibody therapeutics referred to as Biclonics® are designed to recruit the immune system to kill cancer cells and tip the balance in favor of patients with more effective treatments that have less side effects. Ultimately, it is Merus’ goal to help declare victory for patients with this devastating disease to help them lead normal lives. read more Product Candidates Human Biclonics® Biclonics® are designed to possess a format of antibodies that are produced naturally by the immune system, and are designed to retain their favorable attributes including stability, predictability during manufacturing, long half-life and low immunogenicity during treatment of patients. read more all news News Recent news MERUS TO PARTICIPATE IN CITI’S 13TH ANNUAL BIOTECH CONFERENCE MERUS ANNOUNCES FORMATION OF A SCIENTIFIC ADVISORY BOARD MERUS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2018... AUGUST 30, 2018 UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… AUGUST 22, 2018 – Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of… AUGUST 10, 2018 – MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented… the company's presence in 2018 Upcoming events Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events. all events SEPTEMBER 6, 2018 MERUS TO PARTICIPATE IN CITI’S 13TH ANNUAL BIOTECH CONFERENCE Merus to Participate in Citi’s 13th Annual Biotech Conference UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative... read more Merus N.V. Yalelaan 62 3584 CM Utrecht The Netherlands +31 (0)30 - 253 88 00 enquiries@merus.nl Merus US, Inc. One Broadway Cambridge, MA USA +1 (781) 760 - 0013 USenquiries@merus.nl Links Merus Technology Pipeline Careers Investors & Media Publications © All rights reserved. Merus 2018 Design by FPW ― Privacy Statement & Terms of Use